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Abstract
Around half of patients with early psychosis have a history of cannabis use. We
aimed to determine if there are neurobiological differences in these the subgroups of
persons with psychosis with and without a history of cannabis use. We expected to
see regional deflations in hippocampus as a neurotoxic effect and regional inflations
in striatal regions implicated in addictive processes. Volumetric, T1w MRIs were
acquired from people with a diagnosis psychosis with (PwP + C = 28) or without
(PwP − C = 26) a history of cannabis use; and Controls with (C + C = 16) or without
(C − C = 22) cannabis use. We undertook vertex-based shape analysis of the
brainstem, amygdala, hippocampus, globus pallidus, nucleus accumbens, caudate,
putamen, thalamus using FSL FIRST. Clusters were defined through Threshold Free
Cluster Enhancement and Family Wise Error was set at p < .05. We adjusted analyses
for age, sex, tobacco and alcohol use. The putamen (bilaterally) and the right thalamus
showed regional enlargement in PwP + C versus PwP − C. There were no areas of
regional deflation. There were no significant differences between C + C and C − C.
Cannabis use in participants with psychosis is associated with morphological alter-
ations in subcortical structures. Putamen and thalamic enlargement may be related to
compulsivity in patients with a history of cannabis use.
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1 | INTRODUCTION
The use of cannabis by people with a diagnosis of psychosis (PwP) is
associated with worse clinical outcomes. PwP who use cannabis have
an earlier age of psychosis onset (Large, Sharma, Compton, Slade, &
Nielssen, 2011), poorer functioning as indexed by the Global Assess-
ment of Functioning (GAF; Seddon et al., 2015), increased healthcare
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utilisation (Manrique-Garcia et al., 2014; Patel et al., 2016), and
increased rates of relapse (Schoeler et al., 2016). However there is
also evidence that PwP who use cannabis have less severe impair-
ments in cognitive function particularly in the early phase of psychosis
(Schoeler, Kambeitz, & Bhattacharyya, 2015; Stirling, Lewis, Hop-
kins, & White, 2005; Yucel et al., 2012) and display fewer neurological
soft signs (Bersani, Orlandi, Gherardelli, & Pancheri, 2002; Mallet,
Ramoz, Le Strat, Gorwood, & Dubertret, 2017; Mhalla et al., 2017;
Ruiz-Veguilla et al., 2009). The neurobiological basis of these differ-
ences is unclear. One way of addressing this issue is to compare brain
anatomy in PwP with or without a history of cannabis use.
A systematic review (Sami & Bhattacharyya, 2018) demonstrated
that after 5 years of psychosis onset, cannabis using PwP exhibited a
greater degree of grey matter reduction (Rais et al., 2008) and cortical
thinning (Habets, Marcelis, Gronenschild, Drukker, & Van Os, 2011;
Rais et al., 2010) with evidence of longitudinal deterioration (Rais
et al., 2008; Rais et al., 2010) than PwP who did not use cannabis. It is
likely that this evidences either neurotoxic effects of ongoing sub-
stance use or alternatively a distinct trajectory of the psychosis.
However, in the early stages of cannabis use in psychosis
(≤5 years after illness onset), the morphological characterisation has
been less clear. Some studies have shown relative enlargement of hip-
pocampal (Cunha et al., 2013), putamen (Koenders et al., 2015) and
cortical regions (Cunha et al., 2013; Schnell, Kleiman, Gouzoulis-May-
frank, Daumann, & Becker, 2012) and localised increase in the corpus
collosum (Malchow et al., 2013) in PwP with cannabis use compared
to those who do not use the drug. Others have, however, shown
reductions in volume of mediotemporal, striatal, (James et al., 2011),
thalamic (Kumra et al., 2012), cerebellar (Cohen et al., 2012; James
et al., 2011), and cortical regions (James et al., 2011; Rapp
et al., 2013; Szeszko et al., 2007) in PwP with cannabis use compared
to PwP who do not use cannabis. Other studies in early psychosis
have found no volumetric differences between PwP who do and not
use cannabis (Bangalore et al., 2008; Cahn et al., 2004; Haller
et al., 2013).
Taken together, although there is well-replicated evidence for
grey matter reduction of cannabis use in people with longer term psy-
chosis that is, more than 5 years (Habets et al., 2011; Rais et al., 2008;
Rais et al., 2010) the literature is unclear about differences in brain
morphology related to cannabis use in individuals in the earlier phase
of psychosis (i.e., less than 5 years). Possible reasons for variation in
results between studies may be due to differences in regions of inter-
est (brain volume, grey matter, cerebellum, cortical thickness, subcorti-
cal structures), differences in sample composition (enduring psychotic
disorder, schizophrenia spectrum disorder, early psychosis), medica-
tion (whether medication status is accounted for), definition of canna-
bis use consumption (ever use or misuse/dependence) and
differences in which confounders were adjusted for (tobacco and
alcohol). For a full review of these differences see (Sami &
Bhattacharyya, 2018). Taken together it was suggested that in the
early stages of psychosis, cumulative exposure to cannabis has been
shorter than in later stages of psychosis and hence neurobiological
differences between cannabis using and cannabis-free PwP may be
more subtle (Sami & Bhattacharyya, 2018). Therefore, a more sensi-
tive technique may be necessary to detect any group differences.
Most studies to date have undertaken volumetric analysis of
structures which provide a global measure of a structure whilst few
studies have looked at shape analysis. Although volume changes indi-
cate global change in morphology. Shape analysis allows for the
detailed examination of morphometric alterations. Hence the two
analyses may provide complementary information. Analysis of shape
deformation parameterises high-dimensional changes in complex
structures and hence may be more sensitive to regional effects (Gerig,
Styner, Shenton, & Lieberman, 2001). For example, the thalamus
includes 50–60 different nuclei and the amygdala and hippocampi are
similarly amalgamations of distinct substructures (Fanselow &
Dong, 2010; Herrero, Barcia, & Navarro, 2002; Janak & Tye, 2015),
hence, perturbation of any substructure may distort shape with lim-
ited appreciable effect on total volume. Both psychosis and cannabis
use, studied on their own, have been shown to be associated with
subcortical shape changes. In psychotic disorders there are known
alterations in the shape of caudate (Scanlon et al., 2014), hippocampus
(Sauras et al., 2017) and thalamus (Smith et al., 2011) compared to
controls. Cannabis use is associated with enlargement of the nucleus
accumbens and amygdala in recreational users (Gilman et al., 2014)
and regional hippocampal deflation in cannabis dependent PwP (Chye
et al., 2019a).
To date, no study has examined shape changes in the early phase
of psychosis and cannabis use. Three studies have looked at the shape
of subcortical structures in individuals with chronic psychosis with
and without cannabis use. Solowij et al. (2013) examined chronic
patients with schizophrenia with average duration of psychosis
19.1 years. The study demonstrated regional deflations in hippocam-
pus in cannabis users compared to non-users but no difference after
False Discovery Rate correction. Smith et al. (2014) and Smith
et al. (2015) undertook two analyses in a larger sample, finding canna-
bis related shape deformations in hippocampus, striatum, globus
pallidus and thalamus which were associated with cognitive perfor-
mance. These patients were less chronic, albeit average duration of
psychosis was 6.5 years. As shown in our previous Systematic Review
(Sami & Bhattacharyya, 2018) and discussed above, 5 years seems to
be a key period where morphological changes have not been clear,
and this has not been undertaken using shape analyses to date. Study
of these substrates in an earlier sample may help more clearly delin-
eate early markers of pathology distinct from the longer term effects
of psychosis and substance use.
Hence, the aim of the present study was to examine the associa-
tion between cannabis use and the shape of subcortical structures in
individuals in the early phase of psychosis, focusing on the major deep
grey matter regions. After review of previous studies in the field
(Sami & Bhattacharyya, 2018) we also included controls with or with-
out a history of cannabis use. A number of subcortical structures have
been implicated in cannabis and psychosis as outlined above so we
explored this in the main subcortical structures. In line with prior liter-
ature, reviewed above (Chye et al., 2019a; Koenders et al., 2015;
Smith et al., 2015), we had expected to see regional deflations in the
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hippocampus in cannabis using participants with psychosis compared
to non-cannabis using participants with psychosis as a neurotoxic
effect of cannabis; and regional inflations in shape of striatal regions
which are involved in addiction circuitry. We also tested whether
these differences would be evident between controls with and with-
out a history of cannabis use.
2 | METHODS
2.1 | Sample
All data were acquired from the EfCiP study (the Effect of Cannabis in
Psychosis (London-Stanmore REC 17/LO/0577) which recruited four
groups: Early Psychosis individuals with a history of cannabis use
(PwP + C; n = 28), Early Psychosis individuals without a cannabis use
history (PwP − C; n = 26), controls with a history of cannabis use (C
+ C; n = 16) and controls without such a history (C − C; n = 22).
Early Psychosis was defined as first treatment of psychosis within
the last 5 years. One patient under an Early Intervention in Psychosis
team had experienced a psychotic episode 20 years ago at the age of
12 and had been asymptomatic off-treatment until re-presenting in
his 30 s. Cannabis use was defined as use of cannabis ≥20 times in
lifetime but we preferentially recruited for heavy cannabis use in both
PwP and controls. We excluded participants with organic psychosis
and those with substance intoxication on the study day. PwP were
recruited through clinical teams from 16 NHS trusts across England
through the National Institute of Health Research (UK) Clinical
Research Networks.
2.2 | Study day
Participants attended a study day including psychiatric and drug inter-
view schedules and Magnetic Resonance Imaging. Each participant
was assessed with the Structured Clinical Interview for DSM-IV
(SCID-IV; First et al., 1995), GAF(First et al., 1995), and Positive and
Negative Syndrome Scale (PANSS)(Kay, Fiszbein, & Opler, 1987).
National Assessment of Reading Test (NART) was used to index Full
Scale Intelligence Quotient using a recently restandardised calculation
in British adults (Bright, Hale, Gooch, Myhill, & van der Linde, 2018).
Since NART is not valid in Learning Disability where participants had a
previously diagnosed mild Learning Disability they were assigned an
IQ score of 65. Participants were administered the Fagerstrom test
for Nicotine Dependence (Heatherton, Kozlowski, Frecker, &
Fagerström, 1991), the Alcohol Use Disorders Identification Test
(AUDIT; Babor, Higgins-Biddle, Saunders, & Monteiro, 2001), the
Severity Dependence Scale (SDS; Gossop et al., 1995) in relation to
the last month's cannabis use, the TimeLine FollowBack questionnaire
(Sobell & Sobell, 1996) and a modified version of the Cannabis Experi-
ences Questionnaire we have previously used to index quantity of
cannabis and other drug use (Barkus, Stirling, Hopkins, & Lewis, 2006;
Schoeler et al., 2016). Chlorpromazine equivalents were calculated
from the Maudsley Guidelines 12th Edition, or where not available
therein, from Gardener et al. (Gardner, Murphy, O'Donnell,
Centorrino, & Baldessarini, 2010; Taylor, Paton, & Kapur, 2016). As
NART was added after the 20th participant, these data for partici-
pants prior to this were collected subsequently by telephone, with
NART assumed to be stable over time.
2.3 | Image acquisition
Data were acquired using a 32-channel head coil (Nova Medical, Wil-
mington, MA) on a General Electric Healthcare MR750 (Chicago, IL)
3 Tesla system. After a 3-plane localizer for orientation and an ASSET
calibration, T1 weighted volumetric images were acquired using the sag-
ittal ADNI Go Inversion Recovery Spoiled Gradient Echo (IR-SPGR)
sequence with 196 1.2 mm thick slices and an in-plane matrix size of
256 x 256 (1.05 mm × 1.05 mm) (TR/TI/TE: 7.312 ms/400 ms/3.016
ms, flip angle: 11). The field of view was placed to avoid nose wrap.
Total acquisition time was 5 min 37 seconds.
2.4 | Statistical analysis
Demographic, clinical and cannabis use data were investigated using
t-tests for continuous variables and chi-squared tests for categorical
variables. Mann–Whitney U test was used for skewed data and
median and interquartile Range (IQR) reported. Analysis was under-
taken using the SPSS version 25. Imaging data analysis was conducted
as described below.
2.5 | Structural MRI processing
All T1 weighted images were inspected for image quality and evidence
of motion and MRI artefact. We undertook Shape Analysis using an
automated vertex-based approach using the FMRIB laboratory's Inte-
grated Registration & Segmentation Tool (FSL FIRST) (https://fsl.
fmrib.ox.ac.uk/fsl/fslwiki/FIRST). Briefly, this relies on Active Appear-
ance Modelling (AAM) algorithm (Cootes, Edwards, & Taylor, 1998)
which is an optimised shape recognition technique whereby the algo-
rithm is trained using an iterative procedure to minimise residuals
between estimated shape and the gold standard, incorporating both
shape and intensity information of the image. For the purpose of FSL
FIRST this has been trained on a manually labelled dataset of 336 brain
images of 15 structures in both health and disease. The FIRST toolkit
undertakes AAM on the provided data by modelling shape of subcor-
tical structures such that the models from the training set act as a
prior probability in a Bayesian framework (Patenaude, Smith, Ken-
nedy, & Jenkinson, 2011). Firstly, affine transformation was under-
taken to register scans to standard Montreal Neurological Institute
(MNI) space using the 1mm3 isotropic MNI 152 template. Next,
15 subcortical structures (i.e., seven bilateral structures left and right:
amygdala, caudate, hippocampus, nucleus accumbens, pallidum,
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putamen, thalamus and brainstem) were segmented. Segmentations
were manually checked for errors. One scan (PwP + C) was rejected
due to registration failure and was excluded from further analysis.
Having generated vertex-based segmentations—all subcortical
structure files were concatenated into a 4D volume such that
corresponding vertices across subjects were projected onto the aver-
age shape of the cohort. Each image represented a subject and each
projected vertex in the image represented the perpendicular distance
from the corresponding point on the average surface.
For shape analysis we undertook group-wise statistical testing of
surface vertices of subcortical structures using FSL Randomise—a per-
mutation based analysis, a non-parametric method, for inferential
testing (Winkler, Ridgway, Webster, Smith, & Nichols, 2014). Analysis
was undertaken using 10,000 permutations for each subcortical struc-
ture. Using General Linear Models, we tested group effects regressing
out the effects of demeaned covariates: age, sex, AUDIT score (for
alcohol use) and Fagerstrom score (for tobacco use) as covariates of
no interest. Three contrasts were tested in line with our hypotheses:
PwP + C versus PwP − C; all PwP versus all controls; C + C versus C
− C. Clusters were defined through Threshold Free Cluster Enhance-
ment, a cluster-based method of multiple correction using neigh-
bouring vertex information without prior arbitrary definition of a
cluster-forming threshold (Smith & Nichols, 2009) and family wise
error was set at p < .05.
In a further exploratory analysis we undertook a volume-based
analysis of all subcortical structures. From each segmentation we
extracted the volume of each structure for each participant. We
tested the same three contrasts between groups for each structure
using t-tests with Bootstrapped Bias-Corrected accelerated (BCa)
95% confidence intervals (1,000 samples). We report results as signifi-
cant at p < .05. To test whether significant differences would survive
multiple comparison correction we undertook false discovery rate cor-
rection for the volume of each shape within each contrast.
In a secondary analysis (as informed by the results of the primary
analysis) we wished to determine whether the findings seen in PwP
+ C versus PwP − C were similar to those seen in Cannabis Depen-
dence. We consequently undertook the same analyses which have
been described above for a further contrast: those with lifetime Can-
nabis Dependence (as diagnosed by the SICD) versus those without
lifetime Cannabis Dependence across the whole sample. These are
presented in the main manuscript (for surface analyses) and
Supporting Information (for volumetric analyses) alongside the main
findings.
3 | RESULTS
Demographics: Data was available for 54 PwP and 38 controls.
Baseline demographic and clinical data can be seen in Table 1. Of
note there were no clinically significant differences between PwP
+ C and PwP − C groups across all clinical variables: proportion
with schizophrenia spectrum disorder diagnosis, total PANSS scores
and all subscales, GAF scores, days spent in hospital, age at onset
and chlorpromazine equivalent antipsychotic dose. As expected,
there were increased Fagerstrom and AUDIT scores in the PWP
+ C group indexing increased tobacco and alcohol use in PwP with
a history of cannabis use. PwP had lower estimated IQ than
controls.
There was no discernible difference in cannabis use parameters
between patient and control cannabis using groups (PwP + C vs. C
+ C) in terms of extent of use, age of first use, current use and days
since last use (see Table 1). Proportionally more PwP + C met thresh-
old for a lifetime diagnosis of cannabis use disorder (SCID IV abuse or
dependence): there was a trend to increases cannabis misuse in PwP
+ C versus C + C (p = .0503).
Shape: Uncorrected T-maps for the three contrasts can be seen in
Figure 1. After TFCE correction and family wise error p < .05 correc-
tion, the following differences were noted: PwP versus controls: There
were small clusters of enlargements in the right pallidum and left
amygdala for PwP compared to controls (voxels ≤14, see Table 2). The
right pallidum also showed a larger area of deflation in the medial pos-
terior aspect of the pallidum for PwP compared to controls (see
Figure 2). PwP with and without cannabis use (PwP + C vs. PWP − C):
The right and left putamen showed areas of enlargement in the PwP
+ C group on the medial surface which would abutt the pallidum (see
Figure 3). There was a large area of enlargement on the lateral surface
of the right putamen. The right thalamus was enlarged in the PwP + C
group with a large cluster laterally (289 voxels) and at the site of the
massa intermedia.
Volume: In C + C the right accumbens was significantly larger than
C − C Hedge's g 0.67, p = .046). This did not survive FDR correction.
Otherwise there were no significant volumetric differences for any of
the main comparisons (PwP vs. Controls; PwP + C vs. PwP − C and C
+ C vs. C − C) or for the secondary analysis (CanDep+ vs. CanDep−).
Further volume data across groups are shown in Supporting
Information.
4 | DISCUSSION
Our main findings were that there was a bilateral increase in regional
putamen shape bilaterally and in the right thalamus in PwP + C com-
pared to PwP − C; whilst there was no evidence for selective regional
shape deflation across the subcortical regions. There were no shape
changes in controls with and without a history of cannabis use.
The putamen, alongside the caudate, together constitute the dor-
sal striatum which has been implicated in habit learning and compul-
sive behaviour (Everitt & Robbins, 2013). Increased putamen grey
matter volume (Moreno-Alcázar et al., 2018) and cerebral blood flow
(Filbey, Aslan, Lu, & Peng, 2018) have been shown in healthy cannabis
users compared to controls. Increased putamen volume has been
shown to be associated with methamphetamine use (Andres
et al., 2016; Chang et al., 2005; Jan, Lin, Miles, Kydd, & Russell, 2012),
with alterations in putamen myeleoarchitecture in those at behav-
ioural risk of addiction (Nord et al., 2019), and increased putamen vol-
umes in probands with stimulant addiction and relatives of those with
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addictive disorder (Ersche et al., 2012). Two previous studies have
examined cannabis use in the context of psychosis: one showed puta-
men volume increases in cannabis-using compared to non-using PwP
(Koenders et al., 2015), whereas the other found neurochemical
changes in the left putamen with higher NAA/choline ratio in
cannabis-using PwP compared to controls (Malchow et al., 2013). Our
study thus extends their findings by demonstrating regional structural
change using an alternative analytical strategy and confirming the
finding of putamen enlargement in the PwP + C group.
We also find regional enlargement of the right thalamus in
PwP + C compared to PwP − C. Consistent with our findings heavy
cannabis users have been shown to have greater grey matter density
in the right thalamus compared to non users (Matochik, Eldreth,
Cadet, & Bolla, 2005), although volume decrease in cannabis users at
risk for psychosis have also been reported (Kumra et al., 2012; Welch
et al., 2011). The thalamus has a key role in the addiction circuitry and
has been conceptualised to influence addiction pathology via cortico-
striatal-thalamocortical loops (Huang, Mitchell, Haber, Alia-Klein, &
Goldstein, 2018). Thalamic nuclei have been demonstrated to regulate
instrumental learning, behavioural flexibility and behavioural rein-
forcement (Bradfield, Hart, & Balleine, 2013; Lalive, Lien, Roseberry,
Donahue, & Kreitzer, 2018; Marton, Seifikar, Luongo, Lee, &
Sohal, 2018). Cortico–striatal–thalamocortical loops are particularly
implicated in an array of psychopathology with compulsive behaviour
including obsessive compulsive disorder and substance use (Fettes,
Schulze, & Downar, 2017). In contemporary addiction models the dor-
sal striatal-pallidal-thalamic component of the circuit is particularly
important in hardwiring habit formation the behavioural output driv-
ing compulsive use (Everitt & Robbins, 2005; Koob & Volkow, 2016).
Taken together speculatively our findings of morphologically changes
in the putamen and thalamus in PwP + C versus PwP – C, in sub-
strates involved in habit formation, may represent a biomarker of
compulsive use in this group. This may go some way to explaining
why some PwP use cannabis despite clearly adverse consequences. In
TABLE 1 Baseline characteristics between groups
PwP + C (n = 28) PwP − C (n = 26) C + C (n = 16) C + C (n = 22)
Mean SD Mean SD Mean SD Mean SD
Male sex (proportion) 78.6% 65.4% 62.5% 50%
Age 25.49 3.93 26.73 5.15 27.11 5.95 28.16 5.29
Fagerstroma,b (nicotine dependence) 2.68 2.44 0.62 1.50 0.75 1.73 0.00 0.00
AUDITb,c (alcohol use disorders) 8.82 5.40 3.42 4.83 7.75 6.43 3.59 2.99
Days in hospital 53.57 75.26 43.54 61.60
Chlorpromazine equivalent medication dose 189.20 177.34 188.02 173.25
Age of psychosis onset 23.34 4.03 23.66 5.40
Schizophrenia spectrum (proportion) 78.6% 76.9%
PANSS positivea 12.36 5.40 11.50 5.37 7.19 0.54 7.09 0.43
PANSS negativea,c 14.18 7.24 14.65 6.58 8.13 1.59 7.14 0.64
PANSS generala,c 27.50 9.12 27.00 8.90 19.25 3.75 16.82 1.74
PANSS totala,c 54.04 18.32 53.15 17.45 34.56 5.38 31.05 2.13
GAFa,c 69.89 8.95 72.65 11.29 89.25 4.93 93.32 2.64
Estimated IQa 99.95 12.74 99.61 14.35 110.28 6.93 110.23 7.98
Time to use 3.5 g of cannabis (days) 9.89 11.50 7.96 9.27
Age of first use 16.19 2.48 16.00 2.50
THC in urine drug sample (proportion) 42.8% 43.8%
Days since last use Mdn: 62.5 IQR:1–380 Mdn: 7 IQR:1–1,402
Cannabis use disorder (proportion)d 78.6% 50.0%
Cannabis dependence (proportion) 60.7% 37.5%
Note: Significance determined using t-tests for continuous variables, Mann–Whitney U test for skewed data (median and IQR reported); chi-squared for
proportions: p < .05.
Abbreviations: AUDIT, alcohol use disorder identification test; C + C Controls with history of cannabis use; C − C: Controls without history of cannabis
use; GAF, global assessment of functioning; IQ, intelligence quotient; IQR, interquartile range; Mdn, median; PANSS, positive and negative syndrome scale;
SD, standard deviations; THC, tetrahydrocannabinol; PwP + C, early Psychosis with history of cannabis use; PwP − C, early Psychosis without history of
cannabis use.
aSignificant difference patients versus controls, p < .05.
bSignificant difference PwP + C versus PwP − C, p < .05.
cSignificant difference C + C versus C − C, p < .05.
dTrend level difference C + C versus C − C, p = .0503.
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the absence of longitudinal analysis in this group, however, we are
unable to disambiguate whether these changes were secondary to or
pre-existed the cannabis use.
Supporting this interpretation we show similar changes (bilateral
putamen and right thalamic regional enlargements) in the whole sam-
ple in a secondary analysis when we reanalysed the data to compare
F IGURE 1 Vertex based t-maps for subcortical structures across groups. Analysis adjusted for age, sex, AUDIT, and Fagerstrom's scores.
Blue-purple indicates inward shape displacement of first group compared to second group, red-yellow indicates outward shape displacement/
enlargement (see colour bar). Shapes rendered 3D shown in anatomical position in radiological convention (from front, left sided structure is
patient's right). Anatomical Reference images in left column: A, anterior; I, inferior; L, left; P, posterior; R, right; S, superior
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lifetime cannabis dependence versus non dependence. However we
are cautious of labelling these findings as a marker of substance
dependence per se. This was not the main purpose of this study
where we preferentially recruited a sample of PwP. We note a recent
large study examining subcortical morphology found negative effects
of alcohol dependence, positive effects of nicotine dependence and
no main effect for other substance dependence (Chye et al., 2019b)
and so limit our interpretations to those of a sample with early
psychosis.
In PwP we find evidence that cannabis is associated with shape
enlargement in structures involved with compulsive use. We do not
find this in controls but do find increased volume (effect size 0.67) as
compared to non-users in the right nucleus accumbens (ventral stria-
tum). In contemporary models both substrates serve different pur-
poses in addiction circuits with the ventral striatum involved in
mesolimbic reward and impulsive behaviour, and the dorsal striatum
involved in habit formation and compulsive drug-seeking (Everitt &
Robbins, 2013; Koob & Volkow, 2010; Koob & Volkow, 2016). This
raises the possibility of differing neurobiological alterations in
cannabis-using PwP versus otherwise healthy cannabis users. In our
study the parameters of cannabis consumption including quantity,
proportion of current users, and age of first use of cannabis did not
significantly differ between cannabis using groups. Nevertheless,
more individuals had a trend towards lifetime diagnosis of cannabis
use disorder in the PwP + C group than the C + C group (79 vs. 50%).
This is not unexpected given the association between cannabis
dependence and psychosis (Fergusson, Horwood, & Swain-Campbell,-
2003; Wisdom, Manuel, & Drake, 2011) and may be a possible expla-
nation for the neurobiological findings suggesting that the two
cannabis using groups had been at differing stages of the addiction
cycle. Different circuitry may explain why PwP use cannabis whilst in
participants without psychotic disorder, psychotic experiences are
associated with cessation of cannabis use (Sami, Notley, Kouimtsidis,
Lynskey, & Bhattacharyya, 2019). In particular one could speculate
that there is an increase in compulsivity in PwP compared to controls
with a history of cannabis use, which may be associated with cannabis
use disorder. Such a formulation could form the basis of hypothesis
testing for further research though a multimodal approach.
We did not find evidence for regional deflation in cannabis-using
compared to non-using PwP as we had particularly expected in the
TABLE 2 Peak cluster co-ordinates
Cluster no Size Max T-stat x y z
Primary analysis: Psychosis ± cannabis
PwP vs. controls
R pallidum (increase in pts) 1 12 3.27 18 4 4
R pallidum (decrease in pts) 2 52 −4.16 16 −3 1
L amygdala (increase in pts) 3 14 2.83 −26 −6 −27
PwP ± C vs PwP-C
R thalamus (increase in PwP + C) 4 33 2.91 1 −17 6
R thalamus (increase in PwP + C) 5 289 2.89 14 −17 2
R putamen (increase in PwP + C) 6 22 3.17 19 7 1
R putamen (increase in PwP + C) 7 234 3.4 29 9 −5
L putamen (increase in PwP + C) 8 31 3.84 −22 3 3
C ± C vs C-C
None
Secondary analysis: Cannabis dependence
All can-dep ± versus can-dep−
R thalamus (increase in Can-Dep+) 1 1,422 3.81 19 −17 2
R putamen (increase in Can-Dep+) 2 424 4.00 28 14 −5
R putamen (increase in Can-Dep+) 3 84 3.17 15 10 −6
R putamen (increase in Can-Dep+) 4 73 2.91 26 −2 −4
R amygdala (decrease in Can-Dep+) 5 11 −3.10 18 0 −18
R amygdala (decrease in Can-Dep+) 6 9 −3.60 15 −7 −20
R Accumbens (increase in Can-Dep+) 7 3 3.12 9 12 −11
L putamen (increase in Can-Dep+) 8 333 3.81 −29 9 −3
L putamen (increase in Can-Dep+) 9 100 3.16 −21 −3 7
L putamen (increase in Can-Dep+) 10 37 3.61 −20 4 −1
L amygdala (decrease in Can-Dep+) 11 17 −3.01 −23 −2 −14
Note: Significant clusters after threshold free cluster enhancement, family wise error p < .05. Only signifi-
cant surviving clusters shown. Co-ordinates given in mm in MNI space.
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hippocampus. Reductions in volume and shape are considered to be
consistent with an effect of regular cannabis use and are seen in
chronic populations (Rais et al., 2008; Solowij et al., 2013). Longitudi-
nal studies demonstrate that this reduction follows cannabis use (Rais
et al., 2008; Rais et al., 2010; Welch et al., 2011; Welch, Stanfield,
et al., 2011). This may support the view that the reduction in grey
matter seen in long-term users is a cumulative effect of cannabis use
(Sami & Bhattacharyya, 2018).
There are several strengths in this study. We include four groups,
including the control cannabis using group which has often been omit-
ted from similar previous studies (Sami & Bhattacharyya, 2018). The
T1-weighted scans used are isotropic and relatively high resolution
volumetric scans for addressing this question. We undertook segmen-
tation using FSL FIRST which has been shown to be superior to
FreeSurfer for putamen segmentation and comparable to gold stan-
dard expert manual tracing for basal ganglia structures (Perlaki
et al., 2017). We covary for alcohol and tobacco use, as these can
often confound findings and in line with recommendations from
reviews in the field (Murray et al., 2017; Sami & Bhattacharyya, 2018).
Furthermore, importantly the PwP + C and PwP – C patient groups
are well matched across clinical parameters, including diagnosis func-
tioning, symptomatology, days of hospitalisation and medication,
p < .05
p < .05
p = 0
p = 0
F IGURE 2 Bilateral Pallidum
(brown) and Amygdala (purple) masks
overlayed with significant clusters for
all patients versus all controls. A,
anterior; I, inferior; L, left; P,
posterior; R, right; S, superior.
Red-yellow cluster indicates significant
increase in patient group, blue-purple
cluster indicates significant decrease in
patient group (see colour bar). TFCE,
FWE p < .05
(a) (b)
p < .05
p < .05
p = 0
p = 0
F IGURE 3 Legend: Bilateral
Putamen (green) and Thalamic (purple)
masks overlayed with significant
clusters PwP + C versus PWP-C. A,
anterior; I, inferior; L, left; P,
posterior; R, right; S, superior. All
significant clusters indicate increase in
PwP + C group (see colour bar). TFCE,
FWE p < .05
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indicating that any difference found cannot be accounted for by clini-
cal differences. For shape analysis we used stringent criteria for multi-
ple comparisons correction (TFCE, FWE < 0.5). FIRST undertakes
analysis on a structure by structure basis, although it is arguable
whether this would be any different if cluster correction was applied
across the total number of subcortical surface vertices of all shapes.
Notwithstanding this we also note limitations to the study design.
The study was cross-sectional which precludes inference on the pre-
cise nature of causation between groups. We limited analysis to the
subcortical deep grey matter structures and did not look at cortical
thinning, cerebellar volumes, white matter tracts or ventricular
enlargement, which may also be impacted by cannabis use. Further-
more the sample size was relatively modest to detect volumetric dif-
ferences (Koenders et al., 2014) although comparable to previous
such studies in shape (Smith et al., 2014; Smith et al., 2015; Solowij
et al., 2013). For this reason, we did not try to disentangle gender-
specific effects, although there was no significant difference in gender
between groups.
Taken together we have shown a neurobiological distinction
between those in early psychosis with and without a history of canna-
bis use in the form of bilateral regional putamen enlargement. The
putamen and thalamus may be key neurobiological substrates for
compulsivity in the dual diagnosis group and further research should
aim to delineate the behavioural and neurobiological correlates of
these structures.
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